OncoMatch/Clinical Trials/NCT07672262
VA Consolidation in Intermediate-Risk AML
Is NCT07672262 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies multiple treatments including Venetoclax and Azacitidine and Cytarabine ± Anthracycline for acute myeloid leukemia.
Treatment: Venetoclax and Azacitidine · Cytarabine ± Anthracycline — This clinical trial aims to compare the efficacy and safety of venetoclax-based consolidation therapy versus conventional consolidation chemotherapy (intermediate/high-dose cytarabine) in newly diagnosed adult patients with intermediate-risk acute myeloid leukemia (AML). Participants must have achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after induction therapy with venetoclax and azacitidine and are planned to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: Venetoclax + Azacitidine induction therapy (venetoclax, azacitidine) — induction for AML
Achieved first complete remission (CR) or CR with incomplete hematologic recovery (CRi) after ≤ 2 cycles of Venetoclax + Azacitidine (VA) induction therapy
Lab requirements
Kidney function
creatinine clearance ≥ 50 ml/min
Liver function
ast and alt ≤ 3 × uln; total bilirubin ≤ 2 × uln
Cardiac function
lvef ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07672262 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received Venetoclax + Azacitidine induction therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages